Thinking of joining a study?

Register your interest

NCT05062421 | Recruiting | Arthritis, Rheumatoid


Persistence of Biological Treatment and Inhibitors of Jak Kinases in Patients With Rheumatoid Arthritis.
Sponsor:

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

Brief Summary:

One-center observational study aimed at determining the survival of patients with rheumatoid arthritis treated with targeted synthetic disease-modifying drugs (FAMEsd) and biologic disease-modifying drugs (FAMEb). These patients will be administered a series of medications and a follow-up will be carried out to analyze their evolution.

Condition or disease

Arthritis, Rheumatoid

Detailed Description:

One-center observational study aimed at determining the survival of patients with rheumatoid arthritis treated with targeted synthetic disease-modifying drugs (FAMEsd) and biologic disease-modifying drugs (FAMEb). The drugs to be administered to patients are: JAK-type kinase inhibitors. Monoclonal antibodies against TNF. Soluble receptor against TNF. Biosimilar FAMEb. Rituximab. Abatacept. Drugs that block IL6. A follow-up will be carried out at 12, 24, 48, 60, 72 and 84 months from the start of treatment, to analyze how the patient's health improves.

Study Type : Observational
Estimated Enrollment : 540 participants
Official Title: Persistence of Biological Treatment and Inhibitors of Jak Kinases in Habitual Clinical Practice in Patients With Rheumatoid Arthritis. Influence of the Comorbidities.
Actual Study Start Date : April 1, 2021
Estimated Primary Completion Date : December 1, 2026
Estimated Study Completion Date : December 31, 2026

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Criteria
Inclusion Criteria
  • Patients aged ≥18 years.
  • With a diagnosis of Adult Rheumatoid Arthritis according to the 2010 ACR / EULAR criteria.
  • Who have received at least one of the doses of the study drugs.
  • In follow-up in the consultations of the UGC of Rheumatology of the HUVM.
  • With at least two complete evaluations (baseline and final) of clinical variables.
Exclusion Criteria
  • Patients where the medical records lack sufficient baseline and final variables to perform the analysis.
  • Patients in whom more than 50% of the variables to be collected are missing in the data collection.

Persistence of Biological Treatment and Inhibitors of Jak Kinases in Patients With Rheumatoid Arthritis.

Location Details


Please Choose a site



Persistence of Biological Treatment and Inhibitors of Jak Kinases in Patients With Rheumatoid Arthritis.

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations


Recruiting

Spain,

Hospital Universitario Virgen macarena

Sevilla, Spain, 41009

Loading...